Related Experiment Video

Updated: May 25, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K

MIAT: A pivotal oncogenic long noncoding RNA tunning the hallmarks of solid malignancies

Monica M Rostom1, Alaa A Rashwan2, Christina D Sotiropoulou3

  • 1Pharmacology and Toxicology Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, 11835, Cairo, Egypt.

Translational Oncology
|February 27, 2025
PubMed

Insights

Long non-coding RNA (lncRNA) MIAT is an oncogenic regulator in solid tumors, impacting growth, invasion, and metastasis. MIAT shows potential as a cancer biomarker and therapeutic target.

Area of Science:

  • Molecular Biology
  • Genomics
  • Oncology

Background:

  • Long non-coding RNAs (lncRNAs) are key regulators in cellular processes, challenging the
  • Non-coding DNA constitutes a significant portion of the human genome and is implicated in cancer development.
  • lncRNAs play crucial roles in gene regulation and chromatin dynamics.

Purpose of the Study:

  • To review the complex role of myocardial infarction-associated transcript (MIAT) in solid malignancies.
  • To explore the correlation between MIAT expression and cancer patient clinicopathological features.
  • To outline MIAT's biological functions, mechanisms, clinical implications, and therapeutic strategies in carcinogenesis.

Main Methods:

  • Literature review of studies on MIAT in various cancers.
  • Analysis of MIAT's oncogenic functions, including growth, invasion, metastasis, and cell death resistance.
  • Examination of MIAT's correlation with clinicopathological features.

Main Results:

  • MIAT acts as an oncogenic regulator in numerous malignant tumors.
  • MIAT influences cancer cell growth, invasion, metastasis, and drug resistance.
  • MIAT expression correlates with clinicopathological features in cancer patients.

Conclusions:

  • MIAT is a significant oncogenic lncRNA with potential as a cancer biomarker and therapeutic target.
  • Understanding MIAT's role in carcinogenesis is crucial for developing targeted therapies.
  • Further research into MIAT-targeting therapeutic approaches is warranted.
Keywords:
CancerHallmarksLncRNALong Non-coding RNAMIATOncogenicSolid malignancies

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.3K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.8K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K